Please login to the form below
lisdexamfetamine dimesylate
This page shows the latest lisdexamfetamine dimesylate news and features for those working in and with pharma, biotech and healthcare.
Shire claims FDA approval for slow-cooked ADHD drug
top ADHD seller Vyvanse (lisdexamfetamine dimesylate) - which pulled in $2bn in sales last year, a rise of 17% and added another $563m in the first quarter.
Latest news
-
Monica Seles to front Shire’s binge eating disorder campaign
Shire recently won the first approval in the US for a medicine to help people with binge eating disorder with FDA backing for Vyvanse (lisdexamfetamine dimesylate).
-
Shire gets FDA nod for first binge-eating treatment
Vyvanse (lisdexamfetamine dimesylate) has been used to treat attention-deficit hyperactivity disorder (ADHD) for several years and remains Shire's top-selling product; sales rose 19% to reach more than $1bn
-
AbbVie coaxes Shire into discussions with sweetened offer
Shire has a well-established franchise in attention-deficit hyperactivity disorder (ADHD) drugs, currently headed by Vyvanse (lisdexamfetamine dimesylate), but has latterly built up a portfolio of rare disease therapies such
-
Shire's ADHD drug fails in depression trial
Vyvanse (lisdexamfetamine dimesylate) is already Shire's best performing product with sales of just under $900m for the first nine months of 2013 due to its success as a treatment for
-
Shire weathers generic Adderall XR challenge
This was mainly due to strong performances from Shire's biggest selling product, the ADHD treatment Vyvanse (lisdexamfetamine dimesylate), which recorded an increase in revenues of 18 per cent to $257m,
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
